← All trials
NCT05569772
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2023
- Primary completion
- Dec 31, 2027
- Completion date
- Apr 30, 2028
- First posted
- Oct 6, 2022
- Last posted
- Oct 6, 2022
- Enrollment
- 206
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Katholieke Universiteit LeuvenLead sponsor
- AZ Delta RoeselareCollaborator
- University of LiegeCollaborator
- Erasmus University RotterdamCollaborator
- General Hospital GroeningeCollaborator
- Hasselt UniversityCollaborator
- Onze Lieve Vrouw HospitalCollaborator
- Free University of BrusselsCollaborator
- University of AntwerpCollaborator
- ZNA AntwerpenCollaborator
- AZ TurnhoutCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.